PARTI Overview BioXcel Therapeutics, Inc. (Nasdaq: BTAI, the Company) is a biopharmaceutical company built on artificial intelligence (AI) to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. We have utilized cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients lives. We developed a proprietary AI platform to reduce thera...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001104659-26-036214 | EDGAR | 145K words |
| 2025-03-28 | 2024-12-31 | 0001558370-25-003985 | EDGAR | — |
| 2024-03-22 | 2023-12-31 | 0001558370-24-003784 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001558370-23-003940 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001558370-22-003335 | EDGAR | — |
| 2021-03-12 | 2020-12-31 | 0001558370-21-002916 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001558370-20-002196 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001558370-19-001798 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109880 | EDGAR | 96K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011158 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007269 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015629 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010967 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007481 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-018917 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014729 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008597 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017592 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013353 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001558370-22-007805 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001104659-26-038174 | EDGAR | 0K words |
| 2026-03-27 | 0001104659-26-035661 | EDGAR | — |
| 2026-03-11 | 0001104659-26-026409 | EDGAR | — |
| 2026-02-12 | 0001104659-26-013840 | EDGAR | — |
| 2026-02-06 | 0001104659-26-011595 | EDGAR | — |
| 2026-01-20 | 0001104659-26-004787 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002697 | EDGAR | — |
| 2025-12-15 | 0001104659-25-121180 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109732 | EDGAR | — |
| 2025-11-10 | 0001104659-25-108840 | EDGAR | — |
235 total filings indexed. 205 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001720893 |
| Ticker | BTAI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.bioxceltherapeutics.com |
| Listed | 2018-03-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report